Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17
Sophie Agaugué, Edgardo D. Carosella, Nathalie Rouas‐Freiss
Blood (2011) Vol. 117, Iss. 26, pp. 7021-7031
Closed Access | Times Cited: 132

Showing 1-25 of 132 citing articles:

Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape
Malte Mohme, Sabine Riethdorf, Klaus Pantel
Nature Reviews Clinical Oncology (2016) Vol. 14, Iss. 3, pp. 155-167
Closed Access | Times Cited: 528
Immune modulation by mesenchymal stem cells
Wei Jiang, Jianyong Xu
Cell Proliferation (2019) Vol. 53, Iss. 1
Open Access | Times Cited: 489
HLA-G
Edgardo D. Carosella, Nathalie Rouas‐Freiss, Diana Tronik‐Le Roux, et al.
Advances in immunology (2015), pp. 33-144
Closed Access | Times Cited: 341
Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape
Seung Geun Song, Sehui Kim, Jaemoon Koh, et al.
Cancer Immunology Immunotherapy (2021) Vol. 70, Iss. 7, pp. 2035-2048
Closed Access | Times Cited: 113
Antiangiogenic Therapy for Cancer: An Update
Belal Al‐Husein, Maha Abdalla, Morgan Trepte, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2012) Vol. 32, Iss. 12, pp. 1095-1111
Open Access | Times Cited: 211
Reciprocal Relationship between Myeloid-Derived Suppressor Cells and T Cells
Srinivas Nagaraj, Je‐In Youn, Dmitry I. Gabrilovich
The Journal of Immunology (2013) Vol. 191, Iss. 1, pp. 17-23
Open Access | Times Cited: 173
The role of classical and non-classical HLA class I antigens in human tumors
Juergen Bukur, Simon Jasinski, Barbara Seliger
Seminars in Cancer Biology (2012) Vol. 22, Iss. 4, pp. 350-358
Closed Access | Times Cited: 160
Role of non-classical MHC class I molecules in cancer immunosuppression
Grazyna Kochan, David Escors, Karine Breckpot, et al.
OncoImmunology (2013) Vol. 2, Iss. 11, pp. e26491-e26491
Open Access | Times Cited: 145
Granulocytic myeloid derived suppressor cells expand in human pregnancy and modulate T‐cell responses
Natascha Köstlin, Hellen Kugel, Bärbel Spring, et al.
European Journal of Immunology (2014) Vol. 44, Iss. 9, pp. 2582-2591
Open Access | Times Cited: 144
Sonodynamic therapy‐assisted immunotherapy: A novel modality for cancer treatment
Qianyu Zhang, Cuixia Bao, Xiaojun Cai, et al.
Cancer Science (2018) Vol. 109, Iss. 5, pp. 1330-1345
Open Access | Times Cited: 127
Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges
Aifen Lin, Wei‐Hua Yan
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 121
Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy
Aifen Lin, Wei‐Hua Yan
Molecular Medicine (2015) Vol. 21, Iss. 1, pp. 782-791
Open Access | Times Cited: 120
The Dual Role of HLA-G in Cancer
Nathalie Rouas‐Freiss, Philippe Moreau, Joël LeMaoult, et al.
Journal of Immunology Research (2014) Vol. 2014, pp. 1-10
Open Access | Times Cited: 106
Granulocytic Myeloid-Derived Suppressor Cells Accumulate in Human Placenta and Polarize toward a Th2 Phenotype
Natascha Köstlin, Kathrin Hofstädter, Anna‐Lena Ostermeir, et al.
The Journal of Immunology (2015) Vol. 196, Iss. 3, pp. 1132-1145
Open Access | Times Cited: 96
Comprehensive analysis of the association between tumor glycolysis and immune/inflammation function in breast cancer
Wenhui Li, Ming Xu, Yu Li, et al.
Journal of Translational Medicine (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 96
Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets
Ayana R. Kumar, Aswathy R. Devan, Bhagyalakshmi Nair, et al.
Molecular Biology Reports (2021) Vol. 48, Iss. 12, pp. 8075-8095
Open Access | Times Cited: 88
Mesenchymal Stem Cell Mechanisms of Action and Clinical Effects in Osteoarthritis: A Narrative Review
Vilim Molnar, Eduard Pavelić, Kristijan Vrdoljak, et al.
Genes (2022) Vol. 13, Iss. 6, pp. 949-949
Open Access | Times Cited: 48
Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects
Siyuan Wang, Jiaxin Wang, Yu Xia, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Immunomodulatory Properties of HLA-G in Infectious Diseases
Laurence Amiot, Nicolas Vu, Michel Samson
Journal of Immunology Research (2014) Vol. 2014, pp. 1-14
Open Access | Times Cited: 89
HLA‐G promotes myeloid‐derived suppressor cell accumulation and suppressive activity during human pregnancy through engagement of the receptor ILT4
Natascha Köstlin, Anna‐Lena Ostermeir, Bärbel Spring, et al.
European Journal of Immunology (2016) Vol. 47, Iss. 2, pp. 374-384
Open Access | Times Cited: 82
Novel landscape of HLA‐G isoforms expressed in clear cell renal cell carcinoma patients
Diana Tronik‐Le Roux, Julie Renard, Jérôme Verine, et al.
Molecular Oncology (2017) Vol. 11, Iss. 11, pp. 1561-1578
Open Access | Times Cited: 71
New insights into HLA‐G mediated tolerance
Giada Amodio, Rafael Sales de Albuquerque, Silvia Gregori
Tissue Antigens (2014) Vol. 84, Iss. 3, pp. 255-263
Closed Access | Times Cited: 67
HLA-G: A New Immune Checkpoint in Cancer?
Daniëlle Krijgsman, Jessica Roelands, Wouter Hendrickx, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 12, pp. 4528-4528
Open Access | Times Cited: 66
Hypoxia inducible factor-1 mediates the expression of the immune checkpoint HLA-G in glioma cells through hypoxia response element located in exon 2
Layale Yaghi, Isabelle Poras, Renata Toscano Simões, et al.
Oncotarget (2016) Vol. 7, Iss. 39, pp. 63690-63707
Open Access | Times Cited: 64
Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy
Michael Friedrich, Simon Jasinski‐Bergner, Maria‐Filothei Lazaridou, et al.
Cancer Immunology Immunotherapy (2019) Vol. 68, Iss. 10, pp. 1689-1700
Closed Access | Times Cited: 62
Page 1 - Next Page

Scroll to top